

Review began 03/21/2023

Review ended 04/04/2023

Published 04/08/2023

© Copyright 2023

Althaqafi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Risk Factors for Infection With Multidrug-Resistant Gram-Negative Bacteria in a Tertiary Care Hospital in Saudi Arabia: A Case-Control Study

Abdulhakeem Althaqafi ^{1, 2, 3}, Muhammad Yaseen ⁴, Fayssal Farahat ^{5, 6, 7}, Adeeb Munshi ^{1, 2, 3}, Abdulfattah Al-Amri ^{1, 8, 9}, Sabiha Y. Essack ¹⁰

1. College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, SAU 2. Infectious Diseases, King Abdullah International Medical Research Center, Jeddah, SAU 3. Medicine/Infectious Diseases, King Abdulaziz Medical City, Jeddah, SAU 4. Infection Prevention and Control, Bradford Teaching Hospital National Health Service (NHS) Foundation Trust, Bradford, GBR 5. Public Health and Community Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU 6. Public Health and Community Medicine, Menoufia University, Menoufia, EGY 7. Infection Prevention and Control, King Abdulaziz Medical City Riyadh, Riyadh, SAU 8. Microbiology, King Abdullah International Medical Research Center, Jeddah, SAU 9. Microbiology, King Abdulaziz Medical City, Jeddah, SAU 10. Antimicrobial Research Unit, University of Kwazulu-Natal, Durban, ZAF

Corresponding author: Abdulhakeem Althaqafi, althaqafi@yahoo.com

Abstract

Background

The increase in the incidence of multidrug-resistant (MDR) organisms especially Gram-negative bacteria (GNB) in healthcare facilities is a serious cause of concern. This study identified risk factors for the infection with these MDR GNB, such as *Acinetobacter baumannii*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Escherichia coli* to inform healthcare workers about strategies for their containment.

Methods

A case-control study was carried out at a tertiary care hospital where 100 patients with healthcare-associated infections (infections arising 48 hours after admission) caused by MDR GNB were compared with two control groups, i.e., 100 patients with healthcare-associated infections caused by non-MDR GNB (not meeting the criteria of MDR) and 100 patients without infection caused by GNB. MDR bacteria were defined as the ones that were non-susceptible to at least one antibiotic in three or more classes of antibiotics. The data were analyzed using descriptive statistics (frequency and percentage of categorical variables). Multivariate regression analysis was undertaken to identify significant predictors of MDR GNB. Odds ratios with 95% confidence intervals were calculated, and the level of significance was determined at p-value < 0.05.

Results

A total of 388 organisms were isolated during four months (January-April 2015) from 332 patients. Fifty-six (17%) of the patients were infected with more than one organism. Among the MDR bacteria, the most dominant MDR organism was *A. baumannii* (38%), followed by *K. pneumoniae* (31%), *P. aeruginosa* (20%), and *E. coli* (11%). Among the non-MDR organisms, the most dominant was *P. aeruginosa* (47%), followed by *E. coli* (32%), *K. pneumoniae* (18%), and *A. baumannii* (3%).

Patients with MDR organisms compared with the first control group (patients with non-MDR organisms) showed that prior antibiotic use (p-value: 0.001), intensive care unit (ICU) admission (p-value: 0.001), and indwelling medical devices (p-value: 0.005) were significant risk factors for MDR infections. It was also found that the risk factors for MDR GNB infection were the same in the second control group (patients without infection): prior antibiotic use (p-value: 0.002), ICU admission (p-value: 0.001), and indwelling medical devices (p-value: 0.03). Based on the comparison of the two control groups, prolonged hospital stays of more than five days (p-value: 0.001), immunosuppressive therapy (p-value: 0.02), and over 60 years of age (p-value: 0.02) were significant risk factors for non-MDR infection.

Conclusion

The risk factors identified in our study provide guidance to healthcare workers for the prevention and containment of MDR GNB.

Categories: Infectious Disease

Keywords: saudi arabia, colonized, infected, risk factors, multidrug resistance, gram-negative

How to cite this article

Althaqafi A, Yaseen M, Farahat F, et al. (April 08, 2023) Risk Factors for Infection With Multidrug-Resistant Gram-Negative Bacteria in a Tertiary Care Hospital in Saudi Arabia: A Case-Control Study. Cureus 15(4): e37291. DOI 10.7759/cureus.37291

Introduction

Increase in the incidences of multidrug-resistant (MDR) bacteria in healthcare facilities is a significant concern [1]. The World Health Organization (WHO) has published a priority pathogens list (PPL) of antibiotic-resistant bacteria to guide the research and development of new antibiotics. The priority pathogens have been categorized into three major priorities, i.e., critical, high, and medium. The critical priority pathogens include common Gram-negative bacteria (GNB) like carbapenem-resistant *Acinetobacter baumannii* (*A. baumannii*), carbapenem-resistant *Pseudomonas aeruginosa* (*P. aeruginosa*), carbapenem-resistant and third generation cephalosporin-resistant Enterobacteriaceae like *Klebsiella pneumoniae* (*K. pneumoniae*) and *Escherichia coli* (*E. coli*) [2].

Several studies conducted worldwide have shown that GNB have overtaken their Gram-positive counterparts as far as the resistance to common antimicrobials is concerned [3-5]. GNB have a variety of mechanisms to develop resistance to currently used antibiotics. They can rapidly transfer these mechanisms to other bacteria through various mobile genetic elements [6]. Several studies in Saudi Arabia have also found that MDR GNB have become more prevalent than Gram-positive ones, especially *A. baumannii*, *P. aeruginosa*, *K. pneumoniae* and *E. coli*. [7-11].

Identification of risk factors for MDR GNB has important implications for patient care. Several risk factors have been associated with acquiring antibiotic-resistant pathogens in the hospital. Widespread and inappropriate use of antibiotics in the hospital, intensive care unit (ICU) stay, presence of invasive devices, surgical procedures, and severe co-morbid conditions are commonly reported risk factors for infection with MDR GNB. Other risk factors include age >65 years, duration of hospitalization, surgery, wounds (surgical or traumatic), previous antibiotic therapy, especially within 90 days, current antibiotic therapy, mechanical ventilation, urinary catheterization, nasogastric intubation, central venous and peripheral catheters, prior hospitalization and transfer from another unit or hospital [12-14].

This article was previously presented as an abstract in “Patient Safety Forum 2019, Conference Proceedings, Kingdom of Saudi Arabia, Ministry of National Guard Health Affairs” in April 2019. Our study aimed to identify the risk factors for infection with MDR GNB to inform health care workers about the strategies for their containment.

Materials And Methods

Ethical considerations

The study was approved by the Institutional Review Board (IRB) of King Abdullah International Medical Research Center (KAIMRC) in Saudi Arabia (RJ13/032/I) and the Biomedical Research Ethics Committee (BREC) at the University of Kwazulu-Natal (BE279/13). All data were anonymously collected and interpreted. Additionally, all patients signed a general consent form during hospital admission as part of the hospital policy.

Study design setting

The study was conducted from January to April 2015 at King Abdulaziz Medical City (KAMC), a tertiary care hospital in the city of Jeddah in the Western region of Saudi Arabia. KAMC is an over 500-bed tertiary care hospital serving the National Guards and their eligible dependents in the Western region of Saudi Arabia.

Bacterial isolates were collected prospectively from routine clinical samples from patients presenting with bloodstream, respiratory tract, skin, soft tissues, and urinary tract infections. The organisms included: *A. baumannii*, *K. pneumoniae*, *P. aeruginosa*, and *E. coli*. Only organisms with healthcare-associated infections were included in the study using the standard definition of 48 hours after admission [15]. Each organism was included in the study only once, at the time of the first positive result. MDR and non-MDR GNB were included (non-MDR were defined as the GNB that did not meet the definition criteria for MDR). The definition of the MDR by the experts from the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) was used for this study, where MDR were defined as the non-susceptibility to at least one antibiotic agent in three or more classes of antibiotics [16]. Isolates were categorized as MDRs or susceptible based on their minimum inhibitory concentrations (MICs) determined on the automated Vitek® 2 System (bioMérieux, USA) and interpreted according to Clinical and Laboratory Standards Institute (CLSI) guidelines [16].

A case-control design was used to study significant risk factors for the acquisition of MDR organisms by comparing cases (patients infected with MDR) with two control groups. All patients in the three groups were admitted during the four-month period from January to April 2015. The selection of the patients was based on the date of admission, microbiology culture results, and clinical judgment. Cases were matched with both control groups by type of ward (medical, surgical, or ICU) and hospital admission date. Each group consisted of 100 patients, and 300 patients were included in the study. The first control group included patients infected with non-MDR GNB. The second control group comprised patients without infection.

For each patient, the following clinical data were collected prospectively in a checklist of different parts, including diagnosis at admission, type of clinical ward, having received antimicrobials in the past 90 days, previous hospitalization in the past 90 days, prolonged hospital stay (\geq five days), ICU admission, immunosuppressed patients (patients on active malignancy or on chemotherapy, post organ transplant on immunosuppressive medications including steroids, and human immunodeficiency virus (HIV) with CD4 $<$ 200), indwelling medical devices, recent surgery or trauma in the past 90 days, age \geq 60, gender and emergency admission.

Statistical analysis

Data were analyzed using IBM SPSS version 24.0 (IBM Corp., Armonk, NY). Descriptive statistics (frequency and percentage of categorical variables) were used. Multivariate regression analysis was undertaken to identify significant predictors of MDR-GNB. Variables included in multivariate regression analysis are receiving antimicrobials, previous hospitalization, prolonged hospital stay, ICU patients, immunosuppressed, indwelling medical devices, recent surgery or trauma, gender, and emergency admission. Odds ratios with 95% confidence intervals were calculated. The level of significance was determined at p-value $<$ 0.05.

Results

Between January and April 2015, 388 GNB mentioned above were isolated from routine clinical specimens sent for culture and sensitivity from patients admitted to the hospital. These specimens were collected from 332 patients. Fifty-six (17%) of the patients were infected with more than one organism. As mentioned earlier, only organisms with healthcare-associated infections were included in the study. The organisms included were: *A. baumannii* (80), *K. pneumoniae* (94), *P. aeruginosa* (129), and *E. coli* (85). These coincidentally consisted of 194 MDR GNB and 194 non-MDR GNB. Among the MDR bacteria, the most dominant MDR organism was *A. baumannii* (38%), followed by *K. pneumoniae* (31%), *P. aeruginosa* (20%), and *E. coli* (11%). Among the non-MDR organisms, the most dominant was *P. aeruginosa* (47%), followed by *E. coli* (32%), *K. pneumoniae* (18%), and *A. baumannii* (3%).

Among the 100 cases (MDR patients), 51 were male, and 49 were female; 71 patients were admitted through the emergency department, and 29 were elective admissions. Among the 100 control patients (non-MDR patients), 58 were male, and 42 were females; 60 patients were admitted through the emergency department, and 40 were elective admissions. Among the 100 control patients (patients without infection), 53 were male, and 37 were females; 79 were admitted through the emergency department, and 21 were elective admissions. Among the 300 overall patients included in the case-control study, 145 (48%) were male, 155 (52%) were females, and 147 (49%) were above the age of 60 years. Two hundred and thirty-seven (79%) were admitted through the emergency department, and 63 (21%) were elective admissions. As far as the other risk factors are concerned, 186 (62%) received antimicrobial therapy within the last 90 days, 112 (37%) had previous hospitalization within 90 days, 200 (67%) had a prolonged hospital stay of more than five days, 70 (23%) were admitted in the ICU, 72 (24%) received immunosuppressive therapy, 166 (55%) had indwelling medical devices in situ, and 106 (35%) have had recent surgery or trauma (Table 1).

Variables	Number (percentage)	Group			Multivariate regression		Multivariate regression		Multivariate regression	
		MDR	Non-MDR	No infection	MDR GNB vs.non-MDR		MDR GNB vs. No infection		Non-MDR vs. No infection	
					OR (95%CI)	P. value	OR (95%CI)	P. value	OR (95%CI)	P. value
Receiving antimicrobial										
Yes	186 (62.0%)	84 (45.2%)	57 (30.6%)	45 (24.2%)	5.50 (2.19, 13.84)	0.001	3.98 (1.68, 9.44)	0.002	1.13 (0.53, 2.17)	0.72
No	114 (38.0%)	16 (14%)	43 (37.7%)	55 (48.2%)						
Previous hospitalization										
Yes	112 (37.3%)	44 (39.3%)	34 (30.4%)	34 (30.4%)	1.11 (0.51, 2.41)	0.79	1.05 (0.48, 2.33)	0.9	1.06 (0.53, 2.09)	0.88
No	188 (62.7%)	56	66	66						

		(29.8%)	(35.1%)	(35.1%)						
Prolonged hospital stay										
Yes	200 (66.7%)	77 (38.5%)	76 (38.0%)	47 (23.5%)	0.46 (0.19, 1.10)	0.08	1.95 (0.89, 4.26)	0.09	3.37 (1.74, 6.52)	0.001
No	100 (33.3%)	23 (23.0%)	24 (24.0%)	53 (53.0%)						
ICU patients										
Yes	70 (23.3%)	52 (74.3%)	11 (15.7%)	7 (10.0%)	11.11 (4.58, 26.93)	0.001	8.60 (3.28, 22.57)	0.001	1.43 (0.48, 4.29)	0.52
No	230 (76.7%)	48 (20.9%)	89 (38.7%)	93 (40.4%)						
Immunosuppressed										
Yes	72 (24.0%)	18 (25.0%)	33 (45.8%)	21 (29.2%)	0.55 (0.24, 1.27)	0.16	1.22 (0.48, 3.11)	0.68	2.43 (1.18, 5.04)	0.02
No	228 (76.0%)	82 (36.0%)	67 (29.4%)	79 (34.6%)						
Indwelling medical devices										
Yes	166 (55.3%)	79 (47.6%)	50 (30.1%)	37 (22.3%)	2.95 (1.39, 6.27)	0.005	2.43 (1.11, 5.33)	0.03	1.29 (0.67, 2.48)	0.45
No	134 (44.7%)	21 (15.7%)	50 (37.3%)	63 (47.0%)						
Recent surgery or trauma										
Yes	106 (35.3%)	42 (39.6%)	37 (34.9%)	27 (25.5%)	1.41 (0.68, 2.94)	0.36	1.60 (0.75, 3.39)	0.22	1.26 (0.63, 2.54)	0.51
No	194 (64.7%)	58 (29.9%)	63 (32.5%)	73 (37.6%)						
Age										
>60	147 (49%)	55 (50.0%)	55 (50.0%)	37 (40.2%)	0.79 (0.38, 1.66)	0.54	2.54 (1.14, 5.69)	0.02	2.12 (1.13, 3.99)	0.02
<=60	153 (51%)	45 (50.0%)	45 (50.0%)	63 (58.3%)						
Gender										
Male	145 (48.3%)	49 (50.0%)	49 (50.0%)	47 (49.0%)	1.24 (0.60, 2.54)	0.57	1.34 (0.64, 2.78)	0.44	1.34 (0.71, 2.51)	0.36
Female	155 (51.7%)	51 (50.0%)	51 (50.0%)	53 (51.0%)						
Emergency admission										
Yes	237 (79.0%)	71 (44.9%)	87 (55.1%)	79 (47.6%)	0.42 (0.17, 1.05)	0.06	0.45 (0.18, 1.13)	0.09	1.36 (0.57, 3.23)	0.49
No	63 (21.0%)	29 (69.0%)	13 (31.0%)	21 (61.8%)						

TABLE 1: Risk factors for acquisition of multidrug-resistant (MDR) gram-negative bacteria (GNB)

MDR: Multidrug-resistant; GNB: Gram-negative bacteria; OR: Odds Ratio; CI: Confidence Interval

The comparison between patients with MDR organisms and the first control group (patients with non-MDR organisms) showed that previous antibiotic use (odds ratio {OR}: 5.50, 95% CI: 2.19, 13.84, p-value: 0.001), ICU admission (OR: 11.11, 95% CI: 4.58, 26.93, p-value: 0.001), and indwelling medical devices (OR: 3.02, 95% CI: 1.45, 6.33, p-value: 0.005) were the significant risk factors for the MDR infection (Table 1). The comparison between patients with MDR organisms and the second control group (patients without infection) also showed the same risk factors: previous antibiotic use (OR: 3.98, 95% CI: 1.68, 9.44, p-value: 0.002), ICU admission (OR: 8.60, 95% CI: 3.28, 22.57, p-value: 0.001), and indwelling medical devices (OR: 2.43, 95% CI: 1.11, 5.33, p-value: 0.03) as the significant risk factors for the MDR GNB infection. The comparison of the two control groups showed that prolonged hospital stay of more than five days (OR: 3.37, 95% CI: 1.74, 6.52, p-value: 0.001), receiving immuno-suppressive therapy (OR: 2.43, 95% CI: 1.18, 5.04, p-value: 0.02) and above 60 years age (OR: 2.12, 95% CI: 1.13, 3.99, p-value: 0.02) were the significant risk factors for infection by non-MDR organisms (Table 1).

Discussion

The increasing incidence of MDR GNB is of great concern because of their negative impact on morbidity and mortality, exacerbated by the shortage of alternative therapeutic options [17,18]. Identifying patients at high risk of harboring common MDR GNB has important implications for patient care [12]. Our study identified previous antibiotic use, ICU admission, and indwelling medical devices as significant risk factors for the acquisition of MDR GNB, which is consistent with the previous studies [12,19].

The future use of the new WHO recommendations, and in particular, systematic screening based on well-identified risk factors, will enable earlier identification of colonized or infected patients to limit the spread of these microorganisms by taking adequate measures based on evidence-based practices [20].

Kalam et al. (2014) looked at the risk factors for carbapenem-resistant Gram-negative bacteremia. Only adult patients were included in the study. Their results revealed that age > 50 years, septic shock on presentation, ICU stay of > 72 hours, and receiving immunosuppressive medications were the most significant risk factors [21]. Another study was conducted by Mohsenpour et al. (2016) in Iran to identify the risk factors for imipenem-resistant GNB [22]. Their results showed that ICU stays, a history of antibiotic use, and central venous catheter insertion were the most significant risk factors associated with the acquisition of imipenem-resistant GNB [22]. Ting et al. investigated the risk factors for the acquisition of carbapenem-resistant (CR) GNB by comparing CR GNB-infected patients (Group 1) with patients who were infected with non-CR GNB (Group 2) [23]. They found out that previous exposure to antibiotics, especially carbapenem and anti-pseudomonal penicillin, and cephalosporin, together with a longer length of hospital stay, were the most significant risk factors for the development of CR GNB bacteremia [23].

In Saudi Arabia, a study was conducted by Al-Otaibi et al. (2016) in an oncology center to identify the significant risk factors associated with the bacteremia caused by the MDR GNB [24]. The study included both adult and pediatric patients. The bacteria included in the study were *E. coli* (29.5%), *A. baumannii* (18.0%), *Pseudomonas spp.* (16.3%) and *K. pneumoniae* (13.1%). Other organisms included: *Salmonella spp.* (6.5%), *Serratia marcescens* (4.9%), *Enterobacter spp.* (3.24%). Results revealed that ICU admission (32.1%), surgical procedure (23.2%), and having a central line (21.4%) were the most significant risk factors [24]. Another study conducted in Saudi Arabia by Al Hamdan et al. (2022) revealed MDR GNB were most frequently identified in female patients (66.4%) and those aged 20-29 years (21.8%) [25]. The most frequently isolated GNB were *E. coli* (53.8%). Over the two years of the study, *Enterobacter* species had the highest rate of multidrug resistance (86.5%). A significant direct risk factor for the development of MDR GNB was mechanical ventilation for more than three days [25].

Our study found that the MDR GNB *A. baumannii* and *K. pneumoniae* were more dominant than *P. aeruginosa* and *E. coli*. Risk factors like previous antibiotic use, ICU admission, and indwelling medical devices were the significant risk factors in patients who acquired MDR GNB when compared with the other two groups of patients who were infected with non-MDR GNB or did not have an infection. Prolonged hospital stay, immunosuppression, and age were the most significant risk factors in the patients who were infected with non-MDR organisms compared with patients who had no infection. More effective and efficient antimicrobial stewardship programs, together with better infection control practices, especially in ICU, to prevent transmission, are recommended to address the problem. Implementing the WHO recommendations will undoubtedly add an extra dimension to prevent and control MDR GNB infections in healthcare settings [20]. The study has various limitations, including a single-center design and a small number of the patient. Another limitation of the study is that some risk factors were not analyzed, such as long-stay in nursing homes, patients with chronic ulcers, patients on hemodialysis, or patients with burns.

Conclusions

The risk factors for MDR GNBs have not been well studied in Saudi Arabia. *A. baumannii* (38%), followed by *K. pneumoniae* (31%), were the most dominantly isolated organism among MDR bacteria. Our data also revealed that antibiotic therapy, long ICU stays, and indwelling medical devices were the most significant

risk factors in patients infected with MDR GNBs. These data will stress the importance of continuous surveillance systems and antibiotic stewardship programs as strategies for reducing the number of MDR GNBs.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. King Abdullah International Medical Research Center (KAIMRC) Institutional Review Board issued approval RJ13/032/J. The study was approved by the Institutional Review Board (IRB) of King Abdullah International Medical Research Center (KAIMRC) in Saudi Arabia (RJ13/032/J) and the Biomedical Research Ethics Committee (BREC) at the University of Kwazulu-Natal (BE279/13). **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** This work is supported by the Antimicrobial Research Unit (ARU) and College of Health Sciences (CHS) of the University of KwaZulu-Natal and National Research Foundation (NRF) Incentive Funding for Rated Researchers (Grant No. 85595) awarded to S.Y. Essack. The funders had no role in the study design, preparation of the manuscript, or the decision to submit the work for publication. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** Professor S.Y. Essack is the chairperson of the Global Respiratory Infection Partnership (GRIP), sponsored by an unrestricted educational grant from Reckitt and Benckiser (Pty) Ltd. UK. The other author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Acknowledgements

We would like to thank the microbiology laboratory, especially Dr. Abdulfattah, the Section Head, and Dr. Areej Mufty, Consultant Microbiologist for the microbiological investigations.

References

1. Molton JS, Tambyah PA, Ang BS, Ling ML, Fisher DA: The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. *Clin Infect Dis*. 2013, 56:1310-8. [10.1093/cid/cit020](#)
2. Tacconelli E, Carrara E, Savoldi A, et al.: Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis*. 2018, 18:318-27. [10.1016/S1473-3099\(17\)30753-3](#)
3. Zilberberg MD, Shorr AF: Prevalence of multidrug-resistant *Pseudomonas aeruginosa* and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009. *J Hosp Med*. 2013, 8:559-63. [10.1002/jhm.2080](#)
4. Cornaglia G: Fighting infections due to multidrug-resistant Gram-positive pathogens. *Clin Microbiol Infect*. 2009, 15:209-11. [10.1111/j.1469-0691.2009.02737.x](#)
5. Tan TT: "Future" threat of gram-negative resistance in Singapore. *Ann Acad Med Singap*. 2008, 37:884-90.
6. Akova M: Epidemiology of antimicrobial resistance in bloodstream infections. *Virulence*. 2016, 7:252-66. [10.1080/21505594.2016.1159366](#)
7. Saeed NK, Kambal AM, El-Khizzi NA: Antimicrobial-resistant bacteria in a general intensive care unit in Saudi Arabia. *Saudi Med J*. 2010, 31:1341-9.
8. Eltahawy AT, Khalaf RM: Antibiotic resistance among Gram-negative non-fermentative bacteria at a teaching hospital in Saudi Arabia. *J Chemother*. 2001, 13:260-4. [10.1179/joc.2001.13.3.260](#)
9. Memish ZA, Shibl AM, Kambal AM, Ohaly YA, Ishaq A, Livermore DM: Antimicrobial resistance among non-fermenting Gram-negative bacteria in Saudi Arabia. *J Antimicrob Chemother*. 2012, 67:1701-5. [10.1093/jac/dks091](#)
10. Al Johani SM, Akhter J, Balkhy H, El-Saed A, Younan M, Memish Z: Prevalence of antimicrobial resistance among gram-negative isolates in an adult intensive care unit at a tertiary care center in Saudi Arabia. *Ann Saudi Med*. 2010, 30:364-9. [10.4103/0256-4947.67073](#)
11. Aly M, Balkhy HH: The prevalence of antimicrobial resistance in clinical isolates from Gulf Corporation Council countries. *Antimicrob Resist Infect Control*. 2012, 1:26. [10.1186/2047-2994-1-26](#)
12. Patolia S, Abate G, Patel N, Patolia S, Frey S: Risk factors and outcomes for multidrug-resistant Gram-negative bacilli bacteremia. *Ther Adv Infect Dis*. 2018, 5:11-8. [10.1177/2049936117727497](#)
13. Siegel JD, Rhinehart E, Jackson M, Chiarello L: Management of multidrug-resistant organisms in health care settings, 2006. *Am J Infect Control*. 2007, 35:S165-93. [10.1016/j.ajic.2007.10.006](#)
14. Friedmann R, Raveh D, Zartzer E, Rudensky B, Broide E, Attias D, Yinnon AM: Prospective evaluation of colonization with extended-spectrum beta-lactamase (ESBL)-producing enterobacteriaceae among patients at hospital admission and of subsequent colonization with ESBL-producing enterobacteriaceae among patients during hospitalization. *Infect Control Hosp Epidemiol*. 2009, 30:534-42. [10.1086/597505](#)
15. Friedman ND, Kaye KS, Stout JE, et al.: Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. *Ann Intern Med*. 2002, 137:791-7. [10.7326/0003-4819-137-10-200211190-00007](#)
16. Magiorakos AP, Srinivasan A, Carey RB, et al.: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012, 18:268-81. [10.1111/j.1469-0691.2011.03570.x](#)
17. Tumbarello M, Trecarichi EM, De Rosa FG, et al.: Infections caused by KPC-producing *Klebsiella pneumoniae*: differences in therapy and mortality in a multicentre study. *J Antimicrob Chemother*. 2015,

- 70:2133-43. [10.1093/jac/dkv086](https://doi.org/10.1093/jac/dkv086)
18. Capone A, Giannella M, Fortini D, et al.: High rate of colistin resistance among patients with carbapenem-resistant *Klebsiella pneumoniae* infection accounts for an excess of mortality. *Clin Microbiol Infect*. 2013, 19:E23-30. [10.1111/1469-0691.12070](https://doi.org/10.1111/1469-0691.12070)
19. Giacobbe DR, Del Bono V, Trecarichi EM, et al.: Risk factors for bloodstream infections due to colistin-resistant KPC-producing *Klebsiella pneumoniae*: results from a multicenter case-control study. *Clin Microbiol Infect*. 2015, 21:1106.e1-8. [10.1016/j.cmi.2015.08.001](https://doi.org/10.1016/j.cmi.2015.08.001)
20. Implementation manual to prevent and control the spread of carbapenem-resistant organisms at the national and health care facility level: interim practical manual supporting implementation of the Guidelines for the prevention and control of carbapenem-resistant *Enterobacteriaceae*, *Acinetobacter baumannii* and *Pseudomonas aeruginosa* in health care facilities. (2019). <https://apps.who.int/iris/handle/10665/312226>.
21. Kalam K, Qamar F, Kumar S, Ali S, Baqi S: Risk factors for carbapenem resistant bacteraemia and mortality due to gram negative bacteraemia in a developing country. *J Pak Med Assoc*. 2014, 64:530-6.
22. Mohsenpour B, Rouhi S, Mehrdel R, Faraji T, Masaali M, Ramazanzadeh R: Risk factors associated with imipenem-resistance among isolated gram -negative bacteria from patients in Sanandaj Hospitals, Iran. *Avicenna J Clin Microbiol Infect*. 2016, 3:e29989. [10.17795/ajcmi-29989](https://doi.org/10.17795/ajcmi-29989)
23. Ting SW, Lee CH, Liu JW: Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: a retrospective propensity-matched case control study. *J Microbiol Immunol Infect*. 2018, 51:621-8. [10.1016/j.jmii.2016.08.022](https://doi.org/10.1016/j.jmii.2016.08.022)
24. Al-Otaibi FE, Bukhari EE, Badr M, Alrabiaa AA: Prevalence and risk factors of Gram-negative bacilli causing blood stream infection in patients with malignancy. *Saudi Med J*. 2016, 37:979-84. [10.15537/smj.2016.9.14211](https://doi.org/10.15537/smj.2016.9.14211)
25. Al Hamdan AS, Alghamdi AA, Alyousif GF, Hamza FA, Shafey MM, AlAmri AM, Sunki AA: Evaluating the prevalence and the risk factors of gram-negative multi-drug resistant bacteria in eastern Saudi Arabia. *Infect Drug Resist*. 2022, 15:475-90. [10.2147/IDR.S350048](https://doi.org/10.2147/IDR.S350048)